Skip Page Header

Home > Hepatitis C and injecting drug use: impact, costs and policy options.

Kretzschmar, Mirjam and Wiessing, Lucas and Jager, Johannes and Limburg, Wien and Postma, Maarten, eds. (2004) Hepatitis C and injecting drug use: impact, costs and policy options. EMCDDA Scientific Monograph Series; No. 7 Luxembourg: Office for Official Publications of the European Communities.

[img]
Preview
PDF (EMCDDA Monograph 7) - Published Version
1MB

Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph.

A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy.

Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine.

Table of contents
• Part I: Natural history, treatment, quality of life, epidemiology and prevention
• Part II: Models of hepatitis C in injecting drug users
• Part III: Healthcare costs of drug-related hepatitis C infection
• Part IV: Wider costs of drug use
• Part V: Cost-effectiveness of needle and syringe programmes and methadone maintenance


Repository Staff Only: item control page